A clinical trial of a coronavirus vaccine was launched in northern Colorado on Thursday, with its base in Loveland ranch. UCHealth researchers are recruiting people willing to test potential vaccines.
Clinical trials require about 1,500 adults, and researchers are looking for people at higher risk of exposure because of their high levels of contact with other people such as teachers, grocery store workers, first responders, dentists, and other healthcare workers.
“This is an excellent vaccine, and I think the science behind it seems sound,” Dr. Gary Lucasson of the Rocky Mountain Medical Center in Loveland is conducting clinical trials in Northern Colorado. Interview via Zoom. “I hope it will be effective. It seems to be effective in preliminary trials.”
Carrie Hintzman, a resident of Fort Collins and Sports Minister of Fossil Ridge High School, was the first participant and has received her first vaccination. In the recorded interview, she talked about the many teachers, students and coaches she interacted with every day.
In an interview provided by UCHealth, Hintzman said: “I am here today because I just want everything to return to normal.” She said that since the beginning of the pandemic, she has been unable to see her due to the high risk of contracting HIV Their 84-year-old mother or sister, they have been living in a subsidized life.
She said it was difficult to stay at home without seeing family members. She said that at least through preliminary screening, testing and vaccine participation in clinical trials is very easy-she can do it.
Hinzman said: “I don’t want people to die.”
The clinical trial is one of several ongoing trials by the national research team and the second vaccine trial launched with UCHealth, which is currently being conducted for the manufacturer AstraZeneca. The study will include approximately 1,500 Colorado participants, some of whom will be invited based on their UCHealth records, while others will just volunteer to participate and be screened to see if they are good candidates.
Across the country, 30,000 people will participate, and signatories will be monitored for two years to evaluate the safety of the vaccine and whether they are infected with the virus.
Two-thirds of the participants will receive the vaccine, and one-third will receive a placebo. Luckasen, the chief investigator of the clinical research program at UCHealth in Northern Colorado, explained that the researchers will then study whether the vaccine is effective for weeks, months, and up to two years. He said that participants should visit researchers three to four times within two years.
Lucasson said the size of the team is important to get good information about viruses, vaccines and how they interact.
This particular vaccine was developed by Oxford University and the pharmaceutical company AstraZeneca. It is formed by combining an inactive cold virus with a protein visible on the outside of COVID-19, and has no contact with the new coronavirus itself.
Lucasson said that this protein allows the virus to enter human cells and replicate. The idea is that the body will think that it is being attacked by the coronavirus (although it is not) and has strengthened immunity.
Luckasen said in a recorded interview provided by UCHealth: “It’s that simple.” “You boost your immunity by cheating your immune system, and take care of the virus next time it comes, so we are stopping the coronavirus, We are all back to what we like to do.
“There is such a huge demand now. Everyone wants it to work as we all think,” he said.
According to information from UCHealth, preliminary research results recently released indicate that the vaccine can produce an antibody response, and most participants have neutralizing antibodies after one or two doses.
Lucasson said: “In theory, this sounds good.” “The question is how much resistance it will cause, and is it enough to prevent the spread of the virus in the future?”
The Northern Colorado study was initially launched last month, and the first participant, Hintzman, received her vaccination on September 4. It happened in the UK.
After a “comprehensive evaluation and review,” the U.S. Food and Drug Administration said last week that it can safely continue clinical trials, so UCHealth has now launched the study in Northern Colorado and opened the study on Thursday.
Lucasson said that the global delay illustrates the efforts researchers will make for safety.
Luckasen said in an interview with Zoom: “As far as I am concerned, it is very safe. I think the six-week pause is the reason why it is safe for us to know.”
Now the research is underway, and people interested in participating can visit the website (bit.ly/NoCoVaccineStudy) to answer pre-screening questions to see if they meet the conditions. Registration for this study will take place in the next eight weeks and can be done in The Ranch building in Loland only by appointment. Participants will receive the vaccine, but no other compensation.
Lucasson said that he hopes that all 1,500 participants can participate in Thanksgiving, and he hopes that it will not be difficult to find the number of people willing to sign.
He said: “I think that because people want vaccines, we will arouse great attention from society.” He mentioned the recent surge in coronavirus cases, including Northern Colorado, and predicted a surge in cases this fall and winter.
Lucasson said: “The benefit is not the individual, but the community.” “If we can vaccinate a lot of people, I think it bodes well for the community.”
This is one of approximately 40 COVID-19 trials that UCHealth has participated in, one of which is a vaccine produced by Moderna, which was conducted in cooperation with Moderna School of Medicine. Recruitment for this trial ended last week.
According to UCHealth, both clinical trials focused on vaccines supported by the US government plan. The plan aims to accelerate the development and final distribution of safe and effective vaccines, which researchers hope to save lives.
Lucasson said in the press release: “COVID-19 is absolutely affecting everyone at the moment, and everyone wants to return to normal life.” “If we can develop a successful vaccine, then the sooner we do it, the better it will be for everyone. The situation will be better.”